Optimized generation of functional neutrophils and macrophages from patient-specific induced pluripotent stem cells: Ex vivo models of X0-Linked, AR220- and AR470-chronic granulomatous diseases

BioResearch Open Access

Volumn 3, Issue 6, 2014, Pages 311-326

  Brault, Julie ^a,b   Goutagny, Erwan ^a,b   Telugu, Narasimha ^c   Shao, Kaifeng ^c   Baquié, Mathurin ^d   Satre, Véronique ^b   Coutton, Charles ^b   Grunwald, Didier ^e   Brion, Jean Paul ^b   Barlogis, Vincent ^f   Stephan, Jean Louis ^g   Plantaz, Dominique ^b   Hescheler, Jürgen ^c   Krause, Karl Heinz ^d   Šarić, Tomo ^c   Stasia, Marie José ^a,b  

^a LABORATOIRE TIMC IMAG   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF COLOGNE   (Germany)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e Institut de Recher en Sci et Tech pour le Vivant Commissariat a lstate SAEnergie Atomique   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^g HÔPITAL NORD   (France)

Author keywords

chronic granulomatous disease; disease model; induced pluripotent stem cells; macrophages; NADPH oxidase; neutrophils; NOX2; p22phox; p47phox; reactive oxygen species

Indexed keywords

ALKALINE PHOSPHATASE; CYTOCHALASIN B; GENOMIC DNA; GLYCOPROTEIN GP 91; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; MYELOPEROXIDASE; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P22; PROTEIN P47; REACTIVE OXYGEN METABOLITE; STAGE SPECIFIC EMBRYO ANTIGEN 3; STAGE SPECIFIC EMBRYO ANTIGEN 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ARTICLE; CELL DIFFERENTIATION; CELL STRUCTURE; CELL VIABILITY; CFU COUNTING; CHRONIC GRANULOMATOUS DISEASE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOKINE RELEASE; EMBRYOID BODY; ENZYME ACTIVITY; EX VIVO STUDY; EXOCYTOSIS; FIBROBLAST; FLOW CYTOMETRY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; KARYOTYPING; MACROPHAGE; NEUTROPHIL; PHAGOCYTOSIS; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; SKIN BIOPSY; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84937773825     PISSN: None     EISSN: 21647860     Source Type: Journal    
DOI: 10.1089/biores.2014.0045     Document Type: Article

References (56)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-676
2. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-872
3. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-1920
4. Park I-H, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell. 2008;134:877-886
5. González F, Boué S, Izpisúa Belmonte JC. Methods for making induced pluripotent stem cells: reprogramming à la carte. Nat Rev Genet. 2011;12:231-242
6. Fatima A, Kaifeng S, Dittmann S, et al. The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients. PloS One. 2013;8:e83005
7. Raya A, Rodríguez-Pizà I, Guenechea G, et al. Diseasecorrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009;460:53-59
8. Ross CA, Akimov SS. Human-induced pluripotent stem cells: potential for neurodegenerative diseases. Hum Mol Genet. 2014;23:R17-R26
9. Ordonez MP, Goldstein LSB. Using human-induced pluripotent stem cells to model monogenic metabolic disorders of the liver. Semin Liver Dis. 2012;32:298-306
10. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481: 295-305
11. Van den Berg JM, Van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PloS One. 2009;4:e5234
12. Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis. 2010;45:246-265
13. Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol Dis. 2010;44:291-299
14. Matute JD, Arias AA,Wright NAM, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood. 2009;114:3309-3315
15. Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous diseasewith myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood. 2002;100:4344-4350
16. Kang EM, Malech HL. Gene therapy for chronic granulomatous disease. Methods Enzymol. 2012;507:125-154
17. Zhen L, King AA, Xiao Y, et al. Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox. Proc Natl Acad Sci U S A. 1993;90:9832-9836
18. Choi K-D, Vodyanik MA, Slukvin II. Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34 + CD43 + CD45 + progenitors. J Clin Invest. 2009;119: 2818-2829
19. Mukherjee S, Santilli G, Blundell MP, et al. Generation of functional neutrophils from a mouse model of X-linked chronic granulomatous disorder using induced pluripotent stem cells. PLoS ONE. 2011;6:e17565
20. Zou J, Sweeney CL, Chou B-K, et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood. 2011;117:5561-5572
21. Jiang Y, Cowley SA, Siler U, et al. Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease. Stem Cells. 2012;30:599-611
22. Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8:409-412
23. Yu J, Chau KF, Vodyanik MA, Jiang J, Jiang Y. Efficient feeder-free episomal reprogramming with small molecules. PloS One. 2011;6:e17557
24. Shao K, Koch C, Gupta MK, et al. Induced pluripotent mesenchymal stromal cell clones retain donor-derived differences in DNA methylation profiles. Mol Ther. 2013;21: 240-250
25. Choi K-D, Vodyanik M, Slukvin II. Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells. Nat Protoc. 2011;6:296-313
26. Carrichon L, Picciocchi A, Debeurme F, et al. Characterization of superoxide overproduction by the D-Loop(Nox4)-Nox2 cytochrome b(558) in phagocytes-Differential sensitivity to calcium and phosphorylation events. Biochim Biophys Acta. 2011;1808:78-90.
27. Burritt JB, Busse SC, Gizachew D, et al. Antibody imprint of a membrane protein surface. Phagocyte flavocytochrome b. J Biol Chem. 1998;273:24847-24852
28. Hattori K. An improved method of peroxidase reaction combined with Giemsa's stain for blood cells. J Lab Clin Med. 1958;51:829-834
29. Preynat-Seauve O, Suter DM, Tirefort D, et al. Development of human nervous tissue upon differentiation of embryonic stem cells in three-dimensional culture. Stem Cells. 2009; 27:509-520
30. Trocmé C, Gaudin P, Berthier S, et al. Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9. J Biol Chem. 1998;273:20677-20684
31. Nuutila J, Lilius E-M. Flow cytometric quantitative determination of ingestion by phagocytes needs the distinguishing of overlapping populations of binding and ingesting cells. Cytometry. 2005;65:93-102
32. Defendi F, Decleva E, Martel C, Dri P, Stasia MJ. A novel point mutation in the CYBB gene promoter leading to a rare X minus chronic granulomatous disease variant - impact on the microbicidal activity of neutrophils. Biochim Biophys Acta. 2009;1792:201-210
33. Picciocchi A, Debeurme F, Beaumel S, et al. Role of putative second transmembrane region of Nox2 protein in the structural stability and electron transfer of the phagocytic NADPH oxidase. J Biol Chem. 2011;286:28357-28369
34. Bakri FG, Martel C, Khuri-Bulos N, et al. First report of clinical, functional, and molecular investigation of chronic granulomatous disease in nine Jordanian families. J Clin Immunol. 2009;29:215-230
35. Stasia MJ, Mollin M, Martel C, et al. Functional and genetic characterization of two extremely rare cases of Williams-Beuren syndrome associated with chronic granulomatous disease. Eur J Hum Genet. 2013;21:1079-1084
36. Coutton C, Dieterich K, Satre V, et al. Array-CGH in children with mild intellectual disability: a population-based study. Eur J Pediatr. 2014. [Epub ahead of print]; DOI: 10.1007/s00431-014-2367-6
37. Vodyanik MA, Bork JA, Thomson JA, Slukvin II. Human embryonic stem cell-derived CD34 + cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood. 2005;105:617-626
38. Choi K-D, Yu J, Smuga-Otto K, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells. 2009;27:559-567
39. Lieber JG, Webb S, Suratt BT, et al. The in vitro production and characterization of neutrophils from embryonic stem cells. Blood. 2004;103:852-859
40. Saeki K, Saeki K, Nakahara M, et al. A feeder-free and efficient production of functional neutrophils from human embryonic stem cells. Stem Cells. 2009;27:59-67
41. Yokoyama Y, Suzuki T, Sakata-Yanagimoto M, et al. Derivation of functional mature neutrophils from human embryonic stem cells. Blood. 2009;113:6584-6592
42. Karlsson KR, Cowley S, Martinez FO, et al. Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3. Exp Hematol. 2008;36:1167-1175
43. Subramanian A, Guo B, Marsden MD, et al. Macrophage differentiation from embryoid bodies derived from human embryonic stem cells. Stem Cells. 2009;4:29-45
44. Morishima T, Watanabe K, Niwa A, et al. Neutrophil differentiation from human-induced pluripotent stem cells. J Cell Physiol. 2011;226:1283-1291
45. Wilgenburg B van, Browne C, Vowles J, Cowley SA. Efficient, long term production of monocyte-derivedmacrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. PLoS ONE. 2013;8:e71098
46. Anderson JS, Bandi S, Kaufman DS, Akkina R. Derivation of normal macrophages from human embryonic stem (hES) cells for applications in HIV gene therapy. Retrovirology. 2006;3:24
47. Senju S, Haruta M, Matsumura K, et al. Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther. 2011; 18:874-883
48. Yanagimachi MD, Niwa A, Tanaka T, et al. Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions. PloS One. 2013;8:e59243
49. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 1977;270:347-349
50. Tucker KA, Lilly MB, Heck L Jr, Rado TA. Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity. Blood. 1987;70:372-378
51. Côté SC, Pasvanis S, Bounou S, Dumais N. CCR7-specific migration to CCL19 and CCL21 is induced by PGE2 stimulation in human monocytes: Involvement of EP2/EP4 receptors activation. Mol Immunol. 2009;46:2682-2693
52. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686
53. Köker MY, Camciog?. lu Y, Van Leeuwen K, et al. Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients. J Allergy Clin Immunol. 2013;132:1156-1163
54. Sardina JL, López-Ruano G, Sánchez-Sánchez B, Llanillo M, Hernández-Hernández A. Reactive oxygen species: are they important for haematopoiesis?. Crit Rev Oncol Hematol. 2012;81:257-274
55. Urao N, Ushio-Fukai M. Redox regulation of stem/progenitor cells and bone marrow niche. Free Radic Biol Med. 2013;54:26-39
56. Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245-313